Agenus Inc
NASDAQ · AGEN·Lexington, MA·Small-cap·Phase 3
Clinical-stage immuno-oncology company developing checkpoint antibodies and combinations for "cold" tumors. Lead program pairs botensilimab (Fc-enhanced anti-CTLA-4) with balstilimab (anti-PD-1) and is in the Phase 3 BATTMAN trial for MSS metastatic colorectal cancer; the differentiator is botensilimab's next-generation Fc engineering designed to drive responses in checkpoint-resistant solid tumors.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| BOT/BAL Corporate Overview | Corporate overview | April 15, 2026 | 24 |